Checkmate Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Checkmate Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Checkmate Pharmaceuticals Inc Strategy Report
- Understand Checkmate Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals), a subsidiary of Regeneron Pharmaceuticals Inc, is a biotechnology company that discover and develop novel approaches for cancer immunotherapy. The company’s lead product, CMP-001, is a CpG oligonucleotide (CpG-A) that activates differentiated potent activator TLR9 present in tumor infiltrating plasmacytoid dendritic cells (pDC). Checkmate Pharmaceuticals is investigating CMP-001 in combination with various drugs such as nivolumab and pembrolizumab for treatment of PD-1 refractory melanoma, first-line melanoma and Head and Neck Squamous Cell Carcinoma. The company’s product pipeline includes CMP-001-010 for Advanced Refractory Melanoma, CMP-001-011 for First-line Melanoma, CMP-001-007 for First-line HNSCC. Checkmate Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
2nd Floor, 245 Main Street, Cambridge, Massachusetts, 02142
Website
checkmatepharma.com
Telephone
1 617 6823625
No of Employees
30
Industry
Pharmaceuticals and Healthcare
Checkmate Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Cancer Immunotherapy |
| CMP-001 | |
| CMP-001-010 | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Checkmate Pharmaceuticals Inc | Pfizer Inc | Merck & Co Inc | Amgen Inc | Moderna Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | New York | Kenilworth | Thousand Oaks | Cambridge |
| State/Province | Massachusetts | New York | New Jersey | California | Massachusetts |
| No. of Employees | 30 | 83,000 | 69,000 | 25,200 | 3,900 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mike Powell | Chairman | Executive Board | 2015 | 67 |
| Alan Bash | President; Chief Executive Officer | Senior Management | 2022 | 50 |
| Robert Dolski | Chief Financial Officer | Senior Management | 2021 | 52 |
| James Wooldridge | Chief Medical Officer | Senior Management | 2019 | 56 |
| Art Krieg | Chief Scientific Officer | Senior Management | 2015 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer